In a small trial, a personalized cancer vaccine developed by Geneos Therapeutics, combined with an immunotherapy drug, shrank liver tumors in nearly a third of patients with advanced liver cancer. The vaccine, based on mutations specific to each patient's tumor, aims to boost the immune system's ability to recognize and attack hard-to-treat cancers. The promising results suggest a step forward in effective cancer vaccines and may expand the types of cancers that such therapies can treat. Larger trials are being planned to confirm these findings.
In a small trial, nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug saw their tumors shrink, suggesting that vaccines based on mutations only present in a patient's tumor may boost the immune system's ability to recognize and attack hard-to-treat cancers. The study involved 36 patients with hepatocellular carcinoma, and the combination therapy resulted in a 30.1% tumor shrinkage rate, compared to the typical 12-18% response with immunotherapy alone. Larger trials are being planned to confirm these findings.
In a small trial, nearly a third of advanced liver cancer patients who received a personalized vaccine developed by Geneos Therapeutics alongside an immunotherapy drug saw their tumors shrink, a response twice as high as with immunotherapy alone. The vaccine, based on mutations specific to each patient's tumor, aims to boost the immune system's ability to recognize and attack hard-to-treat cancers. The study suggests progress towards effective cancer vaccines and potential expansion to treat various cancer types, with promising results in combining customized vaccines with immunotherapy. Larger trials are being planned to confirm these findings.
